论文部分内容阅读
目的:探究CXCL1在原发性肝癌中的表达及对人肝癌HepG2细胞增殖的影响。方法:应用免疫组织化学技术(SP二步法)检测48例原发性肝癌组织、13正常肝脏组织中CXCL1表达情况;通过CCK8试剂盒检测CXCL1对HepG2细胞增殖能力的影响。结果:CXCL1在77.1%的原发性肝癌组织中表达,同时CXCL1在原发性肝癌组织中的表达高于正常肝脏组织,差异有统计学意义(P<0.01);不同浓度CXCL1处理人肝癌HepG2细胞后,人肝癌HepG2细胞增殖能力明显增强,并且在一定范围内存在明显的剂量效应。结论:CXCL1在原发性肝癌中表达上调;CXCL1能够促进人肝癌HepG2细胞增殖。
Objective: To investigate the expression of CXCL1 in primary hepatocellular carcinoma and its effect on the proliferation of human hepatoma HepG2 cells. Methods: The expression of CXCL1 in 48 primary hepatocellular carcinoma tissues and 13 normal liver tissues was detected by immunohistochemistry (SP two-step method). The effect of CXCL1 on the proliferation of HepG2 cells was detected by CCK8 kit. Results: The expression of CXCL1 was detected in 77.1% of primary hepatocellular carcinoma and the expression of CXCL1 in primary hepatocellular carcinoma was significantly higher than that in normal liver (P <0.01). CXCL1 was treated with different concentrations of CXCL1 in HepG2 After the cells, the proliferation of HepG2 cells was obviously enhanced, and there was obvious dose effect in a certain range. Conclusion: CXCL1 is upregulated in primary hepatocellular carcinoma and CXCL1 can promote the proliferation of human hepatoma HepG2 cells.